Craft

Fagron

Stock Price

€18.7

2024-10-29

Market Capitalization

€1.4 B

2024-10-29

Revenue

€952.2 M

FY, 2025

Fagron Summary

Company Summary

Overview
Fagron’s strategy is focused on optimizing and innovating customized pharmaceutical care in order to widen the therapeutic options of prescribers worldwide. As the leading global company in pharmaceutical compounding, we are supporting the unique selling point of customized medication and improving patients’ quality of life. As the leading company in pharmaceutical compounding, Fagron develops innovative concepts and solutions that respond to the specific and individual wishes of compounding pharmacies all over the world. In Fagron’s Innovation department, over 200 pharmacists are dedicated to developing and providing innovative concepts, products and formulas that will meet the demands of the pharmacist, prescriber and patient.
Type
Public
Status
Active
Founded
1990
HQ
Rotterdam, NL | view all locations
Website
https://www.fagron.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

LocationsView all

23 locations detected

  • Rotterdam, Zuid-Holland HQ

    Netherlands

    182 Lichtenauerlaan

  • Mendota Heights, MN

    United States

    2400 Pilot Knob Rd

  • Nazareth, Vlaanderen

    Belgium

    Venecoweg 20a

  • SP

    Brazil

    Av. Dr. Hugo Beolchi

  • SP

    Brazil

    Av. Dr. Hugo Beolchi, 445 - 14º andar - Jabaquara

  • SP

    Brazil

    Av. Engenheiro Luís Carlos Berrini, 105 - Itaim Bibi

and 17 others

Fagron Financials

Summary Financials

Revenue (FY, 2025)
€952.2M
Gross profit (FY, 2025)
€492.9M
Net income (FY, 2025)
€91.5M
Cash (FY, 2025)
€184.9M
EBIT (FY, 2025)
€145.4M
Enterprise value
$1.6B

Footer menu